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 ABSTRACT  
 
Deafness is one of the most common health conditions in the developed countries, and 
worldwide, an estimated 70 million people are deaf. For people with severe to profound 
hearing loss, a cochlear implant is the only treatment today. The most common forms of 
severe hearing loss and deafness are related to morphological changes in the cochlea. 
Aim: The aim of these studies was to investigate several therapeutic compounds, 
including nucleosides and nucleotides, two types of neurotrophic factors, and two 
oxysterols, to determine if they could preserve spiral ganglion neuron (SGN) survival 
and maintain SGN electrical responsiveness, as determined by measuring electrically-
evoked auditory brainstem response (eABR) in deafened guinea pigs. It was also 
important to investigate the compounds’ effectiveness when delivered into the inner ear 
several weeks after deafening (“Delayed treatment”). In some experiments, the animals 
stayed in the study for several weeks after cessation of treatment to determine if eABR 
thresholds remained and the extent of SGN survival after treatment cessation.  
Methods: All animals in these studies were deafened with the ototoxic compound 
neomycin sulfate by intracochlear or transtympanic infusion. They received a cochlear 
implant and an osmotic pump for inner ear drug delivery. To determine any changes in 
hearing (i.e., SGN electrical responsiveness), eABR was measured weekly. After the 
last measurement cochleae were collected for morphological analysis. 
Results: We found that nucleosides and nucleotides seem to have a trophic effect on 
spiral ganglion neurons, showing low eABR thresholds and a statistically significant 
(p<0.001) SGN survival compared with the control group. Results from the study with 
glial cell line-derived neurotrophic factor (GDNF) showed that delayed GDNF 
treatment helped to prevent loss of electrical responsiveness and auditory nerve cell 
death up to four weeks after GDNF cessation. Cometin, a new neurotrophic factor, 
showed low eABR thresholds but with fewer surviving SGNs. The oxysterols study 
showed a different pattern compared to all our previous studies. In the acute study both 
oxysterols showed low eABR thresholds compared to the control group, but SGN 
survival was equal to the control group that did not received any treatment. In the 
delayed treatment study only one of the oxysterols showed lower eABR thresholds 
during the whole experiment compared to the control group. Despite that, SGN survival 
was equally low in the oxysterol groups and the control group. 
Of the therapeutic agents tested in this study GDNF was most the promising compound. 
 
 
 
